Abstract

Background

Despite numerous advances in the identification of risk factors for the development of severe coronavirus disease 2019 (COVID-19), factors that promote recovery from COVID-19 remain unknown. Natural killer (NK) cells provide innate immune defense against viral infections and are known to be activated during moderate and severe COVID-19. Killer immunoglobulin-like receptors (KIR) mediate NK cell cytotoxicity through recognition of an altered MHC-I expression on infected target cells. However, the influence of KIR genotype on outcome of patients with COVID-19 has not been investigated so far. We retrospectively analyzed the outcome associations of NK cell count and KIR genotype of patients with COVID-19 related severe ARDS treated on our tertiary intensive care unit (ICU) between February and June 2020 and validated our findings in an independent validation cohort of patients with moderate COVID-19 admitted to our tertiary medical center.

Results

Median age of all patients in the discovery cohort (n = 16) was 61 years (range 50–71 years). All patients received invasive mechanical ventilation; 11 patients (68%) required extracorporeal membrane oxygenation (ECMO). Patients who recovered from COVID-19 had significantly higher median NK cell counts during the whole observational period compared to patients who died (121 cells/µL, range 16–602 cells/µL vs 81 cells/µL, range 6–227 cells/µL, p-value = 0.01). KIR2DS5 positivity was significantly associated with shorter time to recovery (21.6 ± 2.8 days vs. 44.6 ± 2.2 days, p-value = 0.01). KIR2DS5 positivity was significantly associated with freedom from transfer to ICU (0% vs 9%, p-value = 0.04) in the validation cohort which consisted of 65 patients with moderate COVID-19.

Conclusion

NK cells and KIR genotype might have an impact on recovery from COVID-19.

Details

Title
Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019
Author
Lesan Vadim 1   VIAFID ORCID Logo  ; Bewarder Moritz 1 ; Metz, Carlos 2 ; Becker, André 2 ; Mang, Sebastian 2 ; Regitz Evi 1 ; Thurner Lorenz 1 ; Neumann, Frank 1 ; Kos, Igor 1 ; Christofyllakis Konstantinos 1 ; Danziger, Guy 2 ; Stilgenbauer Stephan 1 ; Bals, Robert 2 ; Lepper, Philipp M 2 ; Kaddu-Mulindwa Dominic 1 ; Rixecker Torben 2 

 Saarland University Medical Center, University Hospital, Saarland, Department of Internal Medicine I (Oncology, Hematology, Clinical Immunology, Rheumatology), Homburg, Germany (GRID:grid.411937.9) 
 University Hospital, Saarland, Department of Internal Medicine V (Pneumology, Allergology and Critical Care Medicine), Interdisciplinary COVID-19 Center, Homburg, Germany (GRID:grid.411937.9) 
Publication year
2021
Publication date
Dec 2021
Publisher
Springer Nature B.V.
e-ISSN
2197425X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2568398796
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.